Can lupus kidney patients stop treatment? new study tests ianalumab withdrawal

NCT ID NCT06711887

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This 2-year extension study looks at lupus nephritis patients who finished a previous trial of ianalumab. Some patients who responded well will stop treatment to see if their kidney disease stays under control. Others who did not respond or were already on open-label ianalumab will continue the drug. The study will track safety, kidney flares, and the need for other medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ianalumab (a monoclonal antibody that targets B cells)
What this could lead to: If successful, this study could show that some lupus nephritis patients can safely stop treatment without their kidney disease flaring up, and that ianalumab is safe and effective for long-term use.
What could go wrong: This is an extension study, so it builds on earlier results. However, it is still testing safety and how well the drug works over time. There is no guarantee that stopping treatment will be safe for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Locations

Circuit Clinical
RECRUITING

Orchard Park, New York, 14127, United States
Novartis Investigative Site
RECRUITING

Vitória, Espírito Santo, 29055 450, Brazil
Novartis Investigative Site
RECRUITING

Salvador, Estado de Bahia, 40150 150, Brazil
Novartis Investigative Site
RECRUITING

Belo Horizonte, Minas Gerais, 30150-221, Brazil
Novartis Investigative Site
RECRUITING

Santo André, São Paulo, 09090-790, Brazil
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Shantou, Guangdong, 515000, China
Novartis Investigative Site
RECRUITING

Shenzhen, Guangdong, 518037, China
Novartis Investigative Site
RECRUITING

Liuzhou, Guangxi, 545005, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430060, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130041, China
Novartis Investigative Site
RECRUITING

Binzhou, Shandong, 256603, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Chongqing, 400038, China
Novartis Investigative Site
RECRUITING

Guangzhou, 510080, China
Novartis Investigative Site
RECRUITING

Guangzhou, 510280, China
Novartis Investigative Site
RECRUITING

Shanghai, 200080, China
Novartis Investigative Site
RECRUITING

Barranquilla, Atlántico, 080020, Colombia
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Olomouc, 779 00, Czechia
Novartis Investigative Site
RECRUITING

Prague, 128 00, Czechia
Novartis Investigative Site
RECRUITING

Guatemala City, 01010, Guatemala
Novartis Investigative Site
RECRUITING

Guatemala City, 01011, Guatemala
Novartis Investigative Site
RECRUITING

Tuenmen, 999077, Hong Kong
Novartis Investigative Site
RECRUITING

Budapest, H-1097, Hungary
Novartis Investigative Site
RECRUITING

Kuala Lumpur, Kuala Lumpur, 50586, Malaysia
Novartis Investigative Site
RECRUITING

Sibu, Sarawak, 96000, Malaysia
Novartis Investigative Site
RECRUITING

León, Guanajuato, 37160, Mexico
Novartis Investigative Site
RECRUITING

Oaxaca City, 68020, Mexico
Novartis Investigative Site
RECRUITING

Querétaro, 76070, Mexico
Novartis Investigative Site
RECRUITING

Bucharest, 022328, Romania
Novartis Investigative Site
RECRUITING

Singapore, 169608, Singapore
Novartis Investigative Site
RECRUITING

Singapore, S308433, Singapore
Novartis Investigative Site
RECRUITING

Suwon, Gyeonggi-do, 16499, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03722, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 04763, South Korea
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Taichung, 40447, Taiwan
Novartis Investigative Site
RECRUITING

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site
RECRUITING

Bangkok, 10330, Thailand
Novartis Investigative Site
RECRUITING

Bangkok, 10400, Thailand
Novartis Investigative Site
RECRUITING

Chiang Mai, 50200, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.